C10108: Method for Improved Hyaluronic Acid Retention In VivoNovelty:
This technology presents a novel use of hyaluronic acid- (HA) binding peptide to aid in the retention of HA at its injection site. This technology has applications in many areas of medicine.
Value Proposition:
HA is an important component of the extracellular matrix and is used in a variety of treatments in cosmetic, ophthalmic, and rheumatologic medicine for its properties as a filler and a lubricant. However, upon injection, HA has a retention period of only 24 hours. The novel use of HA-binding peptide has the potential to improve HA retention. Advantages of this method include:
• Decrease in number of treatments needed by patient
• Application to treat chronic dry eye syndrome, lubricate joints, or act as cosmetic filler
• Increased interaction with scaffold for tissue engineering applications
Technical Details:
Johns Hopkins researchers have developed a method for increased HA retention in vivo. To achieve this, HA-binding peptide is bonded to a synthetic polymer. As the HA and HA-binding peptide bond, the polymer crosslinks, fixing the HA dose in place at the target location. This method allows HA retention of greater than 24 hours, improving treatment outcome and efficiency.
Looking for Partners:
To develop and commercialize the technology as an improvement upon current treatments requiring the use of HA.
Stage of Development:
Proof of Concept
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
S. A. Untherman et al. Hyaluronic Acid-Binding Scaffold for Articular Cartilage Repair Tissue Eng Part A. 2012 Jun 22. [Epub ahead of print]
